- Home
- SLP vs DRTS Comparison
SLP vs DRTS Comparison
Compare SLP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- DRTS
- Stock Information
- Founded
- SLP 1996
- DRTS 2015
- Country
- SLP United States
- DRTS Israel
- Employees
- SLP N/A
- DRTS N/A
- Industry
- SLP EDP Services
- DRTS Medical/Dental Instruments
- Sector
- SLP Technology
- DRTS Health Care
- Exchange
- SLP Nasdaq
- DRTS Nasdaq
- Market Cap
- SLP 261.0M
- DRTS 274.0M
- IPO Year
- SLP 1997
- DRTS N/A
- Fundamental
- Price
- SLP $13.64
- DRTS $3.00
- Analyst Decision
- SLP Buy
- DRTS Strong Buy
- Analyst Count
- SLP 7
- DRTS 2
- Target Price
- SLP $29.50
- DRTS $8.00
- AVG Volume (30 Days)
- SLP 1.0M
- DRTS 39.2K
- Earning Date
- SLP 07-14-2025
- DRTS 08-13-2025
- Dividend Yield
- SLP N/A
- DRTS N/A
- EPS Growth
- SLP N/A
- DRTS N/A
- EPS
- SLP N/A
- DRTS N/A
- Revenue
- SLP $80,383,000.00
- DRTS N/A
- Revenue This Year
- SLP $19.69
- DRTS N/A
- Revenue Next Year
- SLP $6.95
- DRTS N/A
- P/E Ratio
- SLP N/A
- DRTS N/A
- Revenue Growth
- SLP 20.01
- DRTS N/A
- 52 Week Low
- SLP $12.39
- DRTS $1.93
- 52 Week High
- SLP $42.11
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- SLP 31.12
- DRTS 46.16
- Support Level
- SLP $12.97
- DRTS $2.95
- Resistance Level
- SLP $13.55
- DRTS $3.15
- Average True Range (ATR)
- SLP 0.77
- DRTS 0.14
- MACD
- SLP 0.24
- DRTS -0.02
- Stochastic Oscillator
- SLP 21.93
- DRTS 20.45
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.